Loading
Latest filing published 21 Jun 2021 for Kala Pharmaceuticals, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Only one filing by Robert Bradley Paull is known so far (21 June 2021): a share grant, in KALA BIO, Inc. That is too little to draw conclusions. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration